AKTS
HealthcareAktis Oncology, Inc. · Biotechnology · $1B
What is Aktis Oncology, Inc.?
Aktis Oncology is a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceutical therapies designed to deliver tumor-killing radioisotopes directly to cancer cells. Based in Boston, Massachusetts, the company is building a novel platform aimed at multiple solid tumor types.
Aktis Oncology develops miniprotein radioconjugates — engineered molecules that bind to proteins expressed on tumor cells and deliver radioisotopes to destroy them from within. The company's platform targets multiple cancer indications, including urothelial cancer, breast cancer, non-small cell lung cancer, prostate cancer, and other solid tumors. Revenue generation is not yet the focus; the company is advancing its pipeline through clinical development stages, funded by capital raises typical of early-stage biotechnology firms.
Aktis Oncology was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Miniprotein radioconjugate (MRC) discovery and development platform
- AKY-1189 targeting Nectin-4 for urothelial, breast, and other cancers
- AKY-2519 targeting B7-H3 for prostate, lung, and solid tumors
- Radioisotope delivery technology for precision oncology
Is AKTS a Good Stock to Buy?
UQS Score rates AKTS as Below Average overall, reflecting the realities of its early clinical-stage profile.
The Growth pillar stands out as the clearest positive signal — the company's expanding pipeline and the rapid rise of radiopharmaceuticals as a treatment modality create a meaningful runway. The Risk pillar also registers as Good, suggesting the company's financial structure and operational risk profile are relatively managed for a firm at this stage.
Both the Quality and Moat pillars are rated Weak, which is typical for pre-revenue biotechs with no established commercial franchise. The Valuation pillar reads as Elevated, meaning the market may already be pricing in significant future success.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AKTS pay dividends?
No — Aktis Oncology, Inc. does not currently pay a dividend.
Aktis Oncology does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward research, clinical trials, and pipeline advancement. Investors in AKTS are typically seeking long-term capital appreciation tied to pipeline milestones rather than income distributions.
When does AKTS report earnings?
Aktis Oncology reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline progress rather than revenue or profitability. Investors should monitor updates on clinical trial enrollment and regulatory milestones as key indicators of progress.
For the most recent quarter's results and pipeline updates, visit Aktis Oncology's investor relations page directly.
AKTS Price History
+1.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
AKTS Long-term Outlook
The fundamental outlook for AKTS is shaped by two contrasting forces. On one side, the Growth pillar reflects genuine pipeline momentum — radiopharmaceuticals are an expanding area of oncology, and Aktis holds early-mover positioning in miniprotein radioconjugates. On the other side, the Weak Quality and Moat pillars signal that the company has yet to establish durable commercial advantages, and the Elevated Valuation pillar suggests the current price reflects optimistic assumptions about future clinical outcomes.
Growth drivers
- Expanding clinical pipeline across multiple high-need solid tumor indications
- Growing industry and regulatory interest in targeted radiopharmaceutical therapies
- Potential for partnership or licensing deals as pipeline data matures
Key risks
- Clinical trial failure or delays could significantly reset investor expectations
- Pre-revenue status means continued dependence on external capital raises
- Elevated valuation leaves limited margin of safety if pipeline progress slows
AKTS vs Peers
Aktis Oncology operates in a competitive clinical-stage oncology landscape alongside several other development-stage biotechnology companies.
ORIC focuses on overcoming cancer treatment resistance mechanisms, pursuing a different biological approach than Aktis's radioisotope delivery platform.
uniQure is a gene therapy company targeting neurological and other diseases, representing a distinct modality from Aktis's radiopharmaceutical strategy.
Geron targets hematologic malignancies through telomerase inhibition, contrasting with Aktis's solid tumor radiopharmaceutical focus.
Frequently Asked Questions
What does Aktis Oncology do?
Aktis Oncology develops targeted radiopharmaceutical therapies for cancer. The company's miniprotein radioconjugate platform is designed to bind to proteins on tumor cells and deliver tumor-killing radioisotopes directly to the cancer, potentially reducing damage to surrounding healthy tissue.
Does AKTS pay dividends?
No, Aktis Oncology does not pay a dividend. As a clinical-stage company with no commercial revenue, it reinvests all available capital into research and clinical development. Dividend payments are not typical for companies at this stage of development.
When does AKTS report earnings?
Aktis Oncology reports on a quarterly cadence standard for US-listed companies. Because it is pre-revenue, reports focus on operating expenses and cash position rather than sales or profits. Check the company's investor relations page for the latest schedule and filings.
Is AKTS a good stock to buy?
UQS Score rates AKTS as Below Average overall. The Growth pillar is Strong and the Risk pillar is Good, but Quality and Moat are both Weak, and Valuation is Elevated. This profile suggests meaningful upside potential is already priced in, with significant execution risk remaining. View the full breakdown on UQS Pro.
Is AKTS overvalued?
The UQS Valuation pillar for AKTS is rated Elevated, indicating the current market price reflects optimistic assumptions about future clinical and commercial success. For a pre-revenue biotech, elevated valuations are common but also carry meaningful downside risk if pipeline milestones are missed.
How does AKTS compare to its competitors?
Aktis Oncology competes in the clinical-stage oncology space alongside companies like ORIC Pharmaceuticals, uniQure, and Geron. Each pursues different biological modalities and target indications. Aktis is differentiated by its miniprotein radioconjugate platform, which is a relatively novel approach within the growing radiopharmaceutical sector.
What is AKTS's market cap bracket?
Aktis Oncology is classified as a small-cap company. Small-cap biotechs at the clinical stage typically carry higher volatility and binary risk tied to clinical trial outcomes, but can also offer significant upside if pipeline programs succeed.
Who founded Aktis Oncology?
Aktis Oncology was incorporated in 2020 and was formerly known as HotKnot Therapeutics, Inc. before changing its name in April 2020. Founding team details are publicly available through the company's official disclosures and SEC filings.
Is AKTS a long-term quality investment?
As a long-term quality indicator, AKTS presents a mixed picture. The Strong Growth pillar reflects genuine pipeline potential in a growing therapeutic area, but Weak Quality and Moat pillars indicate the company has not yet built durable competitive advantages. Long-term quality typically improves as clinical and commercial milestones are achieved.
What is the main competitive advantage of Aktis Oncology?
Aktis Oncology's primary differentiator is its miniprotein radioconjugate platform, which is designed to more precisely target tumor-associated proteins than traditional approaches. This platform underpins multiple pipeline candidates across several cancer types, offering potential breadth if the technology proves effective in clinical trials.
What sector does AKTS belong to?
AKTS operates in the Healthcare sector, specifically within clinical-stage oncology and radiopharmaceutical development. Radiopharmaceuticals are an area of growing interest within precision oncology, attracting both scientific and investor attention in recent years.
Is AKTS a growth stock or value stock?
Based on its UQS pillar profile, AKTS leans toward the growth category — the Growth pillar is rated Strong, reflecting pipeline expansion potential. However, the Elevated Valuation pillar means investors are already paying a premium for that growth, which reduces the margin of safety typical of value-oriented investments.
Unlock Full AKTS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare AKTS against peers on quality and valuation
- ✓Track pipeline-stage risk indicators in one dashboard
- ✓Get the complete analyst-grade view with UQS Pro
Pro Analysis
AKTS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 23.0 | 0.8 | 11.0 | 64.7 | 47.1 | 0.0 | -6.3 |
| May 11, 2026 | 29.3 | 13.9 | 11.0 | 64.7 | 67.6 | 0.0 | -0.4 |
| May 10, 2026 | 29.7 | 15.6 | 11.0 | 64.7 | 67.6 | 0.0 | +0.4 |
| Apr 22, 2026 | 29.3 | 13.9 | 11.0 | 64.7 | 67.6 | 0.0 | -3.2 |
| Apr 10, 2026 | 32.5 | 13.9 | 11.0 | 80.9 | 67.6 | 0.0 | -3.8 |
| Apr 5, 2026 | 36.3 | 13.9 | 11.0 | 100.0 | 67.6 | 0.0 | +17.2 |
| Apr 3, 2026 | 19.1 | 23.2 | 11.0 | 0.0 | 70.6 | 0.0 | -0.1 |
| Apr 2, 2026 | 19.2 | 23.3 | 11.0 | 0.0 | 70.6 | 0.0 | — |
AKTS — Pillar Breakdown
Quality
— 0.8/100 (25%)Aktis Oncology, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 64.7/100 (20%)Aktis Oncology, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)Aktis Oncology, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Aktis Oncology, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Aktis Oncology, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AKTS.
Score Composition
Financial Data
More Stock Analysis
How is the AKTS UQS Score Calculated?
The UQS (Unified Quality Score) for Aktis Oncology, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Aktis Oncology, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Aktis Oncology, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.